Prophylaxis

Dr. Carmen Escuriola- Ettingshausen
MD

Dr Carmen Escuriola Ettingshausen is the Director of the Haemophilia Centre Rhein Main - HZRM, Frankfurt-Mörfelden, Germany.

She graduated in medicine at the Johann Wolfgang Goethe-University in Frankfurt from 1985 to 1992. After that, she became resident at the comprehensive care centre for Thrombosis and Haemostasis of the Children´s Hospital at University Hospital of Frankfurt in the department of Paediatrics until 1996, and obtained the Doctor title in 1995. She performed specialist´s training in Paediatrics at the University Hospital of Frankfurt from 1996 until 2000, and since then she was a staff member at the comprehensive care centre for Thrombosis and Haemostasis of the University Hospital of Frankfurt, department of Paediatrics until 2012. In 2012 she founded the Haemophilia Centre Rhein-Main, Frankfurt-Mörfelden.

Dr Escuriola-Ettingshausen’s clinical interests include haemorrhagic disorders with a focus on haemophilias, thrombosis, congenital immunodeficiencies, and hereditary angioedema in both pediatric and adult patients.

Her research interests are Haemorrhagic disorders, particularly in treatment of haemophiliacs and haemophiliacs with inhibitors. Moreover, she is member of the German, Swiss and Austrian Society For Thrombosis and Haemostasis Research (GTH), International Society for Thrombosis and Haemostasis (ISTH) and World Federation of Hemophilia (WFH). She is actively involved in working groups such as the International Prophylaxis Study Group (IPSG) and Board member of PedNet.

Key Publications
  1. A review of immune tolerance induction with Haemate P in haemophilia A, Escuriola Ettingshausen C.; Kreuz,W. Haemophilia 2014. Vol. 20: 333-339.
  2. Inhibitors in patients with haemophilia A. Kreuz, W.; Ettingshausen, C.E. Thromb. Research 2014. In press.
  3. Influence of factor 5 rs6025 and factor 2 rs1799963 mutation on inhibitor development in patients with hemophilia A--an Israeli-German multicenter database study. Kenet,G.; Bidlingmaier,C.; Bogdanova,N.; Ettingshausen,C.E.; Goldenberg,N.; Gutsche,S.; Halimeh,S.; Holzhauer,S.; Kurnik,K.; Limperger,V.; Junker,R.; Nowak-Gottl,U. Thromb. Res. 2014. Vol. 133: 544-549.
  4. The immune tolerance induction (ITI) dose debate: does the International ITI Study provide a clearer picture? Ettingshausen,C.E.; Kreuz,W. Haemophilia. 2013 Vol.19: 12-17.
  5. Factor VIII products and inhibitor development in severe hemophilia A, Gouw,S.C.; van der Bom,J.G.; Ljung,R.; Escuriola,C.; Cid,A.R.; Claeyssens-Donadel,S.; van,Geet C.; Kenet,G.; Makipernaa,A.; Molinari,A.C.; Muntean,W.; Kobelt,R.; Rivard,G.; Santagostino,E.; Thomas,A.; van den Berg,H.M., N.Engl. J. Med. 2013 Vol.368: 231-239.

Current Positions/Chairs:

  • Director
    Haemophilia Centre Rhein Main - HZRM, Frankfurt-Mörfelden, Germany
  • Member
    German, Swiss and Austrian Society For Thrombosis and Haemostasis Research (GTH), the International Society for Thrombosis and Haemostasis (ISTH) and World Federation of Hemophilia (WFH)
  • Board member
    PedNet

Key Institutions

  • Haemophilia Centre Rhein Main - HZRM
    Frankfurt-Mörfelden, Germany

Research Interests

  • Haemorrhagic disorders, particularly in treatment of haemophiliacs and haemophiliacs with inhibitors
  • Thrombosis
  • Congenital immunodeficiencies
  • Hereditary angioedema in both pediatric and adult patients

Publications

December 3, 2015

Hemophilia prophylaxis no longer just for children without inhibitors – increasing use of prophylaxis in other groups (children with inhibitors and adults with and without inhibitors)

Authors
Carcao M, Avila L, Blanchette V, Santagostino E, Escuriola-Ettingshausen C, Leissinger C, Lambert T, Aledort L on behalf of the International Prophylaxis Study Group (IPSG) and Survey Investigators.
Citation
Blood 2015; 126: 3535